Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19

, , ,

On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of their ongoing U.S. study of BNT162b2 were published in the New England Journal of Medicine (NEJM). BNT162b2, which has advanced into a global Phase 3 study, is part of the companies’ mRNA-based vaccine development program against COVID-19. The publication describes key safety and immunogenicity data from the Phase 1 portion of the U.S. trial for the BNT162b2 and BNT162b1 vaccine candidates.

Among the Phase 1 study participants aged 18 to 55 years, the 50% neutralizing geometric mean titers (GMTs) for the two vaccine candidates at the 30-μg dose level on day 28 or day 35 ranged from 1.7 to 4.6 times the GMT of a panel of SARSCoV-2 human convalescent sera (HCS). In addition, 50% neutralizing GMTs among participants 65 to 85 years of age ranged from 1.1 to 2.2 times the GMT of the HCS panel, demonstrating strong immunogenicity in younger and older adults. Further, across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants. Data were initially made available to the public on August 20, 2020 via the online preprint server, medRxiv.

As previously announced, BNT162b2 was selected as the vaccine candidate to advance into a global Phase 2/3 study based on the totality of available data from preclinical and clinical studies . As of today, the trial has enrolled over 37,000 participants.

Tags:


Source: Pfizer
Credit:

Transfection Has Never Been So Easy With Avalanche® Transfection Reagents for Cancer Cells, Primary Cells, And Other Difficult-To-Transfect Cells.Primary Cells, And Other Difficult-To-Transfect Cells.